Immunome Inc. Files 8-K on Operations and Other Events

TL;DR

Immunome dropped an 8-K detailing financials and other key events as of Jan 29, 2025.

AI Summary

Immunome, Inc. filed an 8-K on January 29, 2025, reporting on its Results of Operations and Financial Condition, as well as Other Events. The filing details the company's financial status and significant corporate activities for the period ending January 29, 2025.

Why It Matters

This 8-K filing provides crucial updates on Immunome's financial health and operational developments, which are important for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This filing is a standard 8-K reporting operational and financial information, not indicating any immediate or unusual risks.

Key Players & Entities

• Immunome, Inc. (company) — Registrant
• January 29, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-39580 (identifier) — Commission File Number
• 77-0694340 (identifier) — IRS Employer Identification No.
• 18702 N. Creek Parkway, Suite 100 Bothell, WA 98011 (address) — Address of principal executive offices
• ( 425 ) 939-7410 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
• $217.3 million — ect to report that we had approximately $217.3 million of cash, cash equivalents and marketabl

Filing Documents

• tm254675d1_8k.htm (8-K) — 50KB
• tm254675d1_8kimg001.jpg (GRAPHIC) — 76KB
• tm254675d1_8kimg002.jpg (GRAPHIC) — 17KB
• tm254675d1_8kimg003.jpg (GRAPHIC) — 56KB
• tm254675d1_8kimg004.jpg (GRAPHIC) — 36KB
• tm254675d1_8kimg005.jpg (GRAPHIC) — 32KB
• tm254675d1_8kimg006.jpg (GRAPHIC) — 73KB
• tm254675d1_8kimg007.jpg (GRAPHIC) — 20KB
• 0001104659-25-007198.txt ( ) — 1012KB
• immu-20250129.xsd (EX-101.SCH) — 3KB
• immu-20250129_lab.xml (EX-101.LAB) — 33KB
• immu-20250129_pre.xml (EX-101.PRE) — 22KB
• tm254675d1_8k_htm.xml (XML) — 4KB

02

Item 2.02 Results of Operations and Financial Condition. On January 29, 2025, the Company announced the commencement of an underwritten public offering of its common stock (the Offering). The Company will file with the Securities and Exchange Commission (SEC) a preliminary prospectus supplement (the Preliminary Prospectus Supplement) to its automatic shelf registration statement on Form S-3 (File No. 333-277036), which was filed with the SEC on February 13, 2024, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the Securities Act), relating to the Offering. The Company will include the following disclosure in the Preliminary Prospectus Supplement: "Our financial will not be available to you prior to investing in our common stock in this offering. Based on preliminary estimates and information available to us as of the date of this prospectus supplement, we expect to report that we had approximately $217.3 million of cash, cash equivalents and marketable securities as of December 31, 2024." Our actual financial to our financial closing procedures and any final adjustments that may be made prior to the time our financial results for the year ended December 31, 2024 are finalized and filed with the SEC. Our independent registered public accounting firm has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial data. This estimate should not be viewed as a substitute for financial statements prepared in accordance with accounting principles generally accepted in the United States and it is not necessarily indicative of the results to be achieved in any future period. The information in this Item 2.02 shall not be deemed "fi

01 Other Events

Item 8.01 Other Events. We are filing the following information for the purpose of updating certain aspects of our publicly disclosed description of our business contained in our other filings with the SEC and prior public disclosures. Business Overview and Recent Developments We are a biotechnology company focused on the development of targeted oncology therapies. We believe that the pursuit of novel or underexplored targets will be central to the next generation of transformative therapies, and we are dedicated to developing targeted cancer therapies with first-in-class and best-in-class potential. Our goal is to establish a broad pipeline of preclinical and clinical assets and develop these assets into approved products for commercialization. To support that goal, we pair business development activity with significant investment in our internal discovery programs. We are advancing a pipeline comprising one clinical, one IND-cleared and four preclinical assets. Varegacestat, formerly AL-102 , is an investigational gamma secretase inhibitor (GSI) currently under evaluation in a Phase 3 trial for the treatment of desmoid tumors. Our investigational new drug application (IND) for IM-1021, a receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody-drug conjugate (ADC) received clearance in December 2024, and we expect to initiate a phase 1 trial in the first quarter of 2025. Our other preclinical assets include IM-3050, a fibroblast activation protein (FAP) targeted radioligand therapy (RLT), for which we anticipate submitting an IND in the first quarter of 2025, and three solid tumor ADC potential drug candidates: IM-1617, IM-1340, and IM-1335, all of which are in IND-enabling manufacturing. We also have six additional ADCs currently undergoing lead optimization with development decisions expected later this year and into 2026. In addition to our pipeline assets, our proprietary payload topoisomerase 1 (TOP1) inhibitor, HC74, supports development of ADC

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements about the Company and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "vision," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "promising," "projected," "first step," "ongoing," or the negative of these terms, and similar words or expressions to identify these forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company's preliminary financial results for the quarter ended December 31, 2024; the expansion and advancement of the Company's platform and pipeline and the Company's approach and strategy related to the platform and pipeline; assessments of the clinical efficacy, best-in-class potential, and potential commercial success of varegacestat; the potential of the Company's current and future pipeline to produce first-in-class and/or best-in-class drugs; the Company's expectations with respect to its future performance; the Company's timeline for filing INDs and other regulatory filings, commencing clinical trials, receiving and reporting data from such clinical trials, and seeking regulatory approval, for one or more of the Company's current or future programs and product candidates and other anticipated milestones; and other statements regarding the management's intentions, plans, beliefs, expectations or forecasts for the future. These forward-looking statements are based on the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the st

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IMMUNOME, INC. Date: January 29, 2025 By: /s/ Clay Siegall Clay Siegall, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR